Attached files
file | filename |
---|---|
EX-31.2 - EX-31.2 - TCR2 THERAPEUTICS INC. | tcrr-20210630ex31_2.htm |
EX-31.1 - EX-31.1 - TCR2 THERAPEUTICS INC. | tcrr-20210630ex31_1.htm |
10-Q - 10-Q - TCR2 THERAPEUTICS INC. | tcrr-20210630.htm |
Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL
FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002
In connection with this Quarterly Report on Form 10‑Q of TCR2 Therapeutics Inc. (the “Company”) for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that, to the best of his or her knowledge:
Dated: August 5, 2021
/s/ Garry E. Menzel |
Garry E. Menzel |
President, Chief Executive Officer and Director (Principal Executive Officer) |
/s/ Mayur (Ian) Somaiya |
Mayur (Ian) Somaiya |
Chief Financial Officer (Principal Financial Officer and Accounting Officer) |